ISSN (Print) - 0012-9976 | ISSN (Online) - 2349-8846
-A A +A

Pharmaceuticals : Misleading Promotion

PHARMACEUTICALS misleading data and suppression of clinical information by drug companies. These are some of the issues that must become part Misleading Promotion The recent court proceedings of the case against GlaxoSmithkline (GSK) in the US have reopened the debate and concerns over the use and acceptance of unpublished data in licensing applications. One outcome has been a change in the regulatory structure and process that ought to be of significance to regulatory authorities everywhere, especially where it is as yet to develop fully.

Subscribers please login to access full text of the article.

New 3 Month Subscription
to Digital Archives at

826for India

$50for overseas users

Get instant access to the complete EPW archives

Subscribe now


(-) Hide

EPW looks forward to your comments. Please note that comments are moderated as per our comments policy. They may take some time to appear. A comment, if suitable, may be selected for publication in the Letters pages of EPW.

Back to Top